Combination Chemotherapy Plus Infusion of White Blood Cells in Treating Patients With Hematologic Cancer
NCT00003243
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. White blood cells from donors may be able to kill cancer cells in patients who have hematologic cancer that has recurred following bone marrow transplantation. PURPOSE: Phase I trial to study the effectiveness of combination chemotherapy plus infusion of donated white blood cells in treating patients who have hematologi... Read More
Gender:
ALL
Ages:
All
Trial Updated:
03/09/2010
Locations: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland
Conditions: Leukemia, Lymphoma, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
Register for Updates
Cyclophosphamide Plus Bone Marrow Transplantation in Treating Patients With Hematologic Cancer
NCT00006042
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Bone marrow transplantation may be able to replace immune cells that were destroyed by chemotherapy or radiation therapy used to kill cancer cells. PURPOSE: Phase I trial to study the effectiveness of cyclophosphamide plus bone marrow transplantation in treating patients who have hematologic cancer.
Gender:
ALL
Ages:
70 years and below
Trial Updated:
03/09/2010
Locations: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland
Conditions: Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
Register for Updates
Chemotherapy in Treating Women With Breast Cancer That Can Be Surgically Removed
NCT00002707
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known if chemotherapy given before surgery is more effective with or without docetaxel given before or after surgery for breast cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of chemotherapy using doxorubicin and cyclophosphamide with or without docetaxel in treating women who have stage II or stage III breast cancer.
Gender:
FEMALE
Ages:
All
Trial Updated:
02/02/2010
Locations: Franklin Square Hospital Center, Baltimore, Maryland +2 locations
Conditions: Breast Cancer
Register for Updates
Phase II Study of High-Dose Cyclophosphamide in Patients With Refractory Pemphigus
NCT00010413
Completed
OBJECTIVES: I. Determine the response rate and 1-year event-free survival of patients with refractory pemphigus treated with high-dose cyclophosphamide.
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
10/01/2008
Locations: Johns Hopkins University School of Medicine, Baltimore, Maryland
Conditions: Pemphigus
Register for Updates
Phase II Study of High-Dose Cyclophosphamide in Patients With Severe Autoimmune Hematologic Disease
NCT00010387
Completed
OBJECTIVES: I. Determine the response rate and 1-year event-free survival in patients with severe autoimmune hematologic disease treated with high-dose cyclophosphamide.
Gender:
ALL
Ages:
All
Trial Updated:
09/08/2008
Locations: Johns Hopkins Oncology Center, Baltimore, Maryland
Conditions: Anemia, Hemolytic, Autoimmune, Felty Syndrome, Purpura, Thrombocytopenic, Autoimmune Diseases
Register for Updates
A Dose Study of Doxil in a Dose Dense, 14 Day CDOP/Rituximab Regimen for Patients With Diffuse Large B-Cell Non-Hodgkin Lymphoma (NHL)> 60 Years or With Compromised Cardiac Status.
NCT00333008
Unknown
The purpose of this study is to evaluate the feasibility and tolerability of delivering a full dose, on time schedule of dose-dense CDOP-R (cyclophosphamide, doxil, vincristine, prednisone, and rituximab) in NHL.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/25/2006
Locations: Sinai Hospital of Baltimore, Baltimore, Maryland +1 locations
Conditions: Diffuse Large B Cell Lymphoma, Lymphoma, Non-Hodgkin
Register for Updates
Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia.
NCT00131313
Unknown
This research study measures the safety and efficacy of the combination of three drugs that are approved, Nipent, Rituxan and Cytoxan in the treatment of Chronic Lymphocytic Leukemia (CLL). These drugs are being given together for investigational purposes as the specific combination of these three drugs has not been approved for treatment of CLL by the FDA.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/17/2005
Locations: Greater Baltimore Medical Center, Baltimore, Maryland +2 locations
Conditions: Chronic Lymphocytic Leukemia
Register for Updates
Pilot Study of Cyclophosphamide in Patients With Life-Threatening Systemic Lupus Erythematosus or Antiphospholipid Antibody Syndrome
NCT00010400
Completed
OBJECTIVES: I. Determine the induction of durable remission in patients with life-threatening systemic lupus erythematosus or antiphospholipid antibody syndrome treated with cyclophosphamide. II. Determine the toxicity of this drug in these patients.
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
06/23/2005
Locations: Johns Hopkins University School of Medicine, Baltimore, Maryland +1 locations
Conditions: Systemic Lupus Erythematosus, Antiphospholipid Antibody Syndrome
Register for Updates